Literature DB >> 1379154

Secondary hypertension. An overview of its causes and management.

D H Streeten1, G H Anderson.   

Abstract

Primarily hypervolaemic, high output forms of hypertension, with features indicating or strongly suggesting fluid overload as the cause of elevated cardiac output, resulting from renal disease with reduced glomerular filtration rate causing sodium retention, renal tubular causes of sodium retention, greatly excessive sodium intake and low renin hypertension, can be treated by reduction of sodium intake and potentiation of its excretion by diuretic therapy, removal of the cause (e.g. aldosteronoma), and calcium antagonists. Excessive vasoconstriction resulting from noradrenaline (norepinephrine) in neurogenic hypertension, phaeochromocytoma, orthostatic hypertension and alpha-adrenergic drug administration; angiotensin excess due to renal ischaemia brought about by aortic coarctation, renal arterial and arteriolar stenosis, intraluminal obstruction, external renal compression, renin-producing tumours, intrinsic kidney diseases and excessive renin substrate; and vascular structural disorders such as atherosclerosis, arteriolitides and fibrosis with or without calcification of major arteries may also induce hypertension. Secondary hypertension of uncertain mechanism may occur in hyperparathyroidism, hyper-or hypothyroidism, or acromegaly. All are best treated by appropriate correction of the endocrine excess or deficiency. It may also occur in pregnancy, where the mechanism may involve prostaglandin-thromboxane imbalance or calcium deficiency; calcium deficiency with some evidence of benefit from calcium supplements; and the recumbent hypertension paradoxically associated with autonomic failure. Excellent responses to specific correction of the underlying cause or pathogenetic mechanism is usual in young individuals but less frequent in older patients.

Entities:  

Mesh:

Year:  1992        PMID: 1379154     DOI: 10.2165/00003495-199243060-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  112 in total

1.  Hypertension associated with endothelin-secreting malignant hemangioendothelioma.

Authors:  K Yokokawa; H Tahara; M Kohno; K Murakawa; K Yasunari; K Nakagawa; T Hamada; S Otani; M Yanagisawa; T Takeda
Journal:  Ann Intern Med       Date:  1991-02-01       Impact factor: 25.391

Review 2.  Clinical review 1: Endocrine hypertension.

Authors:  J C Melby
Journal:  J Clin Endocrinol Metab       Date:  1989-10       Impact factor: 5.958

3.  Catecholamines-cyclic amp-angiotensin receptors. Plasma catecholamine concentrations in patients with hypertension.

Authors:  K Engelman; B Portnoy; A Sjoerdsma
Journal:  Circ Res       Date:  1970-07       Impact factor: 17.367

4.  Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction.

Authors:  A Blumberg; W B Nelp; R M Hegstrom; B H Scribner
Journal:  Lancet       Date:  1967-07-08       Impact factor: 79.321

5.  Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure.

Authors:  H R Brunner; H Gavras; J H Laragh
Journal:  Lancet       Date:  1973-11-10       Impact factor: 79.321

6.  Hypertension after successful renal transplantation.

Authors:  J J Curtis; R G Luke; P Jones; A G Diethelm; J D Whelchel
Journal:  Am J Med       Date:  1985-08       Impact factor: 4.965

7.  Effect of age on response of secondary hypertension to specific treatment.

Authors:  D H Streeten; G H Anderson; S Wagner
Journal:  Am J Hypertens       Date:  1990-05       Impact factor: 2.689

Review 8.  Preeclampsia: a review of the role of prostaglandins.

Authors:  S A Friedman
Journal:  Obstet Gynecol       Date:  1988-01       Impact factor: 7.661

9.  Therapeutic effect of calcium channel blockade in primary aldosteronism.

Authors:  J L Nadler; W Hsueh; R Horton
Journal:  J Clin Endocrinol Metab       Date:  1985-05       Impact factor: 5.958

10.  Renovascular hypertension identified by captopril-induced changes in the renogram.

Authors:  G G Geyskes; H Y Oei; C B Puylaert; E J Mees
Journal:  Hypertension       Date:  1987-05       Impact factor: 10.190

View more
  4 in total

Review 1.  The management of pregnancy in hypertensive patients.

Authors:  R D Tunbridge
Journal:  Postgrad Med J       Date:  1994-11       Impact factor: 2.401

2.  AHSG gene variant is associated with leanness among Swedish men.

Authors:  Catharina Lavebratt; Sofia Wahlqvist; Louise Nordfors; Johan Hoffstedt; Peter Arner
Journal:  Hum Genet       Date:  2005-04-02       Impact factor: 4.132

3.  Predictors of resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenoma.

Authors:  Ra Mi Kim; Jandee Lee; Euy-Young Soh
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

4.  Characterization and history of arterial hypertension leading to inpatient treatment.

Authors:  Carsten P Bramlage; Mina Nasiri-Sarvi; Joan Minguet; Peter Bramlage; Gerhard Anton Müller
Journal:  BMC Res Notes       Date:  2016-10-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.